Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

por van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., Beijnen, J. H.
Publicado 1997

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

por Tellingen, O van, Huizing, M T, Panday, V R Nannan, Schellens, J H M, Nooijen, W J, Beijnen, J H
Publicado 1999

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

por van der Wall, E., Nooijen, W. J., Baars, J. W., Holtkamp, M. J., Schorangel, J. H., Richel, D. J., Rutgers, E. J., Slaper-Cortenbach, I. C., van der Schoot, C. E., Rodenhuis, S.
Publicado 1995

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

por de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Publicado 2003

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

por Verra, N, Jansen, R, Groenewegen, G, Mallo, H, Kersten, M J, Bex, A, Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Nooijen, W J, de Waal, M, Horenblas, S, de Gast, G C
Publicado 2003